The Finlay Vaccine Institute (IFV) posted on Twitter the review of supplies by Dr. Reynaldo Puga and Dr. Yariset Ricardo, senior researcher and coordinator of Soberana Pediatría candidate, respectively, at the Juan Manuel Márquez Children´s Hospital.
The blood collection kits will facilitate the evaluation of immunogenicity of the Soberana 02, Soberana Plus and Abdala vaccines in children under 20 years of age. Regarding Abdala candidate, has been applied to 592 children and young people aging 12 and 18 years, residing in urban areas of Camaguey province.
On Tuesday, children aging 3 to 11 years of age received the last dose of the heterologous anti-Covid-19 scheme approved for Soberana Pediatría clinical trial with Soberana Plus vaccine, a study in which 350 volunteers of those ages and up to 18 years were involved.
According to IFV, the heterologous scheme administered in pediatric study showed 91.2% effectiveness against symptomatic disease in phase III clinical trials in adults.
The same evaluation revealed a 75.7% on the infection and 100% to prevent serious or severe cases.
pgh/Pll/oda / nmr